Workflow
无人机产品及服务
icon
Search documents
光启技术董事长刘若鹏: 坚持研发投入 不断推动超材料技术创新突破
Core Viewpoint - The company is committed to increasing its investment in research and development in the field of metamaterials, aiming to drive continuous innovation and application across various industries [1]. Group 1: Company Development and Achievements - Over 15 years, the company has transformed metamaterial technology from laboratory research to large-scale production, establishing a complete industrial chain [2]. - The company has expanded its production capacity by setting up new research and production bases in Zhuzhou, Tianjin, and Leshan, in addition to existing facilities in Foshan and Luoyang [2]. - The company has achieved full-capacity production at its Foshan and Luoyang bases, with new bases expected to alleviate delivery pressure and enhance production efficiency [2]. Group 2: Core Competitiveness - The company identifies its core competitiveness in three areas: advanced metamaterial technology, significant cost control through digital transformation, and strong order delivery capabilities [3]. - The introduction of the Metamaterials 4.0 technology group is expected to enhance aerospace equipment performance and create new product categories [3]. Group 3: Industrial Ecosystem Construction - The company is focused on building a complete industrial ecosystem for metamaterials, integrating around 2,000 upstream and downstream enterprises to foster innovation and high-quality development [4]. - The industrial layout includes upstream raw material research, midstream key component manufacturing, and downstream end products and services, creating a comprehensive industrial chain [4]. Group 4: Application Expansion - The company is actively expanding the application of metamaterials in various fields, including smart vehicles and robotics, addressing technical challenges and improving performance [7]. - Future developments will focus on integrating sensing and semiconductor technologies, leading to fundamental changes in industrial models [7].